RecruitingNot ApplicableNCT07651761

Patient-Centered Practical Vaccine Talk For Busy Clinicians

Patient-Centered Practical Vaccine Talk for Busy Clinicians (PCP-VAX): An Educational Intervention for Primary Care Providers on Influenza and COVID-19 Vaccine Uptake Among Adult Primary Care Patients

Sponsor

University of Massachusetts, Worcester

Enrollment

24,500 participants

Start Date

Jul 15, 2026

Study Type

INTERVENTIONAL

Conditions

COVID-19 Influenza

Summary

The goal of this study is to assess the effect of an educational intervention for primary care providers (PCPs) on influenza and COVID-19 vaccine uptake among their adult patients through a pragmatic, cluster randomized trial in primary care clinics.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Provider communication training for people with covid-19 and influenza. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERProvider communication training

Providers in participating intervention clinics will complete an educational program (PCP-VAX) on strategies for communicating with patients about the influenza and COVID-19 vaccines.

Locations(1)

UMass Chan Medical School

Worcester, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07651761

Related Trials

Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies

NCT047721701 location

Serological and PCR Testing for COVID-19

NCT044040621 location

Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine

NCT076551801 location

Prevalence and Clinical Significance of Anti-annexin A2 Antibodies in COVID-19 Infection

NCT052421591 location

Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90 mg, Under Fasting and Fed Conditions.

NCT076455341 location